Recently, another beneficial effect of PPARγ/Nrf2 activation in cancer cells has been reported in a rat model of paclitaxel-induced neuropathic pain Rosiglitazone has been shown to revert the downregulation of PPARγ occurring in the spinal cord of rats showing paclitaxel-induced neuropathic pain, and reduce the pain, probably through the increased expression of Nrf2/HO-1 [103]. The gene discussed is NFE2L2; the disease is cancer.